The role of asymmetric dimethylarginine in the pathogenesis of vascular disease in diabetes mellitus
https://doi.org/10.24884/1682-6655-2012-11-4-91-94
Abstract
Diabetes mellitus is one of the most common chronic diseases worldwide and represents a challenge for the healthcare system, mainly because of the life-threatening complications. Endothelial dysfunction is an early marker of vascular complications in the patients with diabetes mellitus. Asymmetric dimethylarginine (ADMA) is generally known as a marker of cardiovascular risk which may be also involved in diabetes mellitus. The results of the studies on the role of ADMA in the patients with diabetes mellitus remain controversial. In this review, we summarize recent data on the relationship between ADMA levels and endothelial dysfunction resulting in vascular complications of diabetes mellitus.
About the Authors
E. N. Kravchuk
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
M. M. Galagudza
V. A. Almazov Federal Center of Heart, Blood and Endocrinology; I. P. Pavlov State Medical University
Russian Federation
Russian Federation
A. A. Karpov
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
A. V. Fedorov
V. A. Almazov Federal Center of Heart, Blood and Endocrinology
Russian Federation
Russian Federation
R. N. Rodionov
Technical University of Dresden
Russian Federation
Russian Federation
References
1. Родионов, Р. Н. Асимметричный диметиларгинин и его роль в этиологии и патогенезе сердечно-сосудистых заболеваний / Р. Н. Родионов [и др.] // Артериальная гипертензия. - 2008. - Т. 14. - № 4. - С. 306-314.
2. Рябов, С. И. Внутренние болезни / С. И. Рябов, В. А. Алмазов, Е. В. Шляхто. - СПб.:Спецлит., 2001. - 861 с.
3. Abbasi, F. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus / F. Abbasi [et al] // Am. J. Cardiol. - 2001. - Vol. 88. - № 10. - P. 1201-1203.
4. Abhary, S. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines / S. Abhary [et al] // Diabetes Care. - 2009. - Vol. 32. - № 11. - P. 2084-2086.
5. Altinova, A. E. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations / A. E. Altinova [et al] // J. Clin. Endocrinol. Metab. - 2007. - Vol. 92. - № 5. - P. 1881-1885.
6. Anderssohn, M. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: An intriguing interaction with diabetes mellitus / M. Anderssohn [et al.] // Diab. Vasc. Dis. Res. - 2010. - Vol. 7. - № 2. - P. 105-118.
7. Anthony, S. Endogenous production of nitric oxide synthase inhibitors / S. Anthony [et al.] // Vasc. Med. - 2005. - Vol. 10. - Suppl. 1. - P. S3-S9.
8. Boger, R. H. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease / R. H. Boger [et al.] // Circulation. - 1997. - Vol. 95. - № 8. - P. 2068-2074.
9. Boger, R. H. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia / R. H. Boger [et al.] // Circulation. - 1998. - Vol. 98. - № 18. - P 1842-1847.
10. Boger, R. H. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia / R. H. Boger [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2000. - Vol. 20. - № 6. - P. 1557-1564.
11. Boger, R. H. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community / R. H. Boger [et al.] // Circulation. - 2009. - Vol. 119. - № 12. - P. 1592-1600.
12. Cavusoglu, E. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography / E. Cavusoglu [et al.] // Atherosclerosis. - 2010. - Vol. 210. - № 1. - P. 226-231.
13. Cooke, J. P. Asymmetrical dimethylarginine: the Uber marker? / J. P. Cooke // Circulation. - 2004. - Vol. 109. - № 15. - P. 1813-1818.
14. Didion, S. P. Impaired endothelium-dependent responses and enhanced influence of Rho-kinase in cerebral arterioles in type II diabetes / S. P. Didion [et al.] // Stroke. - 2005. - Vol. 36. - № 2. - P. 342-347.
15. Eid, H. M. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin / H. M. Eid [et al.] // Atherosclerosis. - 2003. - Vol. 166. - № 2. - P. 279-284.
16. Ellger, B. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity / B. Ellger [et al.] // Endocrinology. - 2008. - Vol. 149. - № 6. - P. 3148-3157.
17. Gunnett, C. A. Gene-targeted mice reveal a critical role for inducible nitric oxide synthase in vascular dysfunction during diabetes / C. A. Gunnett [et al.] // Stroke. - 2003. - Vol. 34. - № 12. - P. 2970-2974.
18. Hanai, K. Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes / K. Hanai [et al.] // Nephrol. Dial. Transplant. - 2009. - Vol. 24. - № 6. - P. 1884-1888.
19. Heilman, K. Elevated plasma adiponectin and decreased plasma homocysteine and asymmetric dimethylarginine in children with type 1 diabetes / K. Heilman [et al.] // Scand. J. Clin. Lab. Invest. - 2009. - Vol. 69. - № 1. - P. 85-91.
20. Howard, B. V. Prevention conference VI: diabetes and cardiovascular disease: writing group I: epidemiology / B. V. Howard [et al.] // Circulation. - 2002. - Vol. 105. - № 18. - P. e132-e137.
21. Jehlicka, P. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1 / P. Jehlicka [et al.] // Physiol. Res. - 2009. - Vol. 58. - № 2. - P. 179-184.
22. Kanazawa, I. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus /I. Kanazawa [et al.] // Clin. Endocrinol. - 2011. - Vol. 74. - № 4. - P. 467-472.
23. Konukoglu, D. The relationship between plasma asymmetrical dimethyl-l-arginine and inflammation and adhesion molecule levels in subjects with normal, impaired, and diabetic glucose tolerance / D. Konukoglu [et al.] // Metabolism. - 2008. - Vol. 57. - № 1. - P 110-115.
24. Lee, I. S. Specific expression of alanine-glyoxylate aminotransferase 2 in the epithelial cells of Henle's loop /1. S. Lee [et al.] // Nephron. - 1999. - Vol. 83. - № 2. - P 184-185.
25. Leiper, J. Disruption of methylarginine metabolism impairs vascular homeostasis / J. Leiper [et al.] // Nat. Med. - 2007. - Vol. 13. - № 2. - P. 198-203.
26. Lin, K. Y. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase / K. Y. Lin [et al.] // Circulation. - 2002. - Vol. 106. - № 8. - P. 987-992.
27. Marcovecchio, M. L. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes / M. L. Marcovecchio [et al.] // Clin. Sci. - 2008. - Vol. 115. - № 12. - P. 361-369.
28. Mittermayer, F. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus / F. Mittermayer [et al.] // Wien. Klin. Wochenschr. - 2005. - Vol. 117. - № 23-24. - P. 816-820.
29. Miyazaki, H. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis / H. Miyazaki [et al.] // Circulation. - 1999. - Vol. 99. - № 9. - P 1141-1146.
30. Nijveldt, R. J. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality / R. J. Nijveldt [et al.] // Clin. Nutr. - 2003. - Vol. 22. - № 1. - P. 23-30.
31. Ogawa, T. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney / T. Ogawa [et al.] // J. Biol. Chem. - 1989. - Vol. 264. - № 17. - P. 10205-10209.
32. Ogawa, T. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine: glyoxylate aminotransferase 2 / T. Ogawa [et al.] // J. Biol. Chem. -1990. - Vol. 265. - № 34. - P 20938-20945.
33. Paiva, H. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerularfiltration rate but not with risk factors of vasculopathy / H. Paiva [et al.] //Metabolism. - 2003. - Vol. 52. - № 3. - P. 303-307.
34. Pettersson, A. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia / A. Pettersson [et al.] // Acta Obstet. Gynecol. Scand. - 1998. - Vol. 77. - № 8. - P. 808-813.
35. Siroen, M. P. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? / M. P. Siroen [et al.] // Crit. Care Med. - 2005. - Vol. 33. - № 3. - P. 504-510.
36. Stojanovic, I. The importance of l-arginine metabolism modulation in diabetic patients with distal symmetric polyneuropathy / I. Stojanovic [et al.] // J. Neurol. Sci. - 2012. - DOI: 10.1016/j.jns.2012.09.026.
37. Sugai, M. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients / M. Sugai [et al.] // Endocr. J. - 2007. - Vol. 54. - № 2. - P. 303-309.
38. Surdacki, A. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension / A. Surdacki [et al.] // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33. - № 4. - P. 652-658.
39. Sydow, K. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity / K. Sydow [et al.] // Arterioscler. Thromb. Vasc. Biol. - 2008. - Vol. 28. - № 4. - P. 692-697.
40. Tarnow, L. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes / L. Tarnow [et al.] // Diabetes Care. - 2004. - Vol. 27. - № 3. - P 765-769.
41. Usui, M. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure / M. Usui [et al.] // Life Sci. - 1998. - Vol. 62. - № 26. - P 2425-2430.
42. Valkonen, V. P. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine / V. P. Valkonen [et al.] // Lancet. - 2001. - Vol. 358. - P 2127-2128.
43. Wild, S. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 / S. Wild [et al.] // Diabetes Care. - 2004. - Vol. 27. - P. 1047-1053.
44. Woodman, R. J. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy / R. J. Woodman [et al.] // Drugs. - 2005. - Vol. 65. - P. 31-74.
45. Xiong, Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes / Y. Xiong [et al.] // Life Sci. - 2005. - Vol. 77. - P. 149-159.
46. Yoo, J. H. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke / J. H. Yoo, S. C. Lee // Atherosclerosis. - 2001. - Vol. 158. - № 2. - P. 425-430.
47. Zoccali, C. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study / C. Zoccali [et al.] // Lancet. - 2001. - Vol. 358. - P. 2113-2117.
Review
For citations:
Kravchuk E.N., Galagudza M.M., Karpov A.A., Fedorov A.V., Rodionov R.N. The role of asymmetric dimethylarginine in the pathogenesis of vascular disease in diabetes mellitus. Regional blood circulation and microcirculation. 2012;11(4):91-94. (In Russ.) https://doi.org/10.24884/1682-6655-2012-11-4-91-94
Views:
435
Email this article 
